VisserWH, de VriendRHM, JaspersNMWH, FerrariMD.Sumatriptan in clinical practice: a two year review of 453 migraine patients. Neurology1996; 47: 46–51
2.
DahlöfC, RimanE.How does the IHS Classification perform in a European Headache Clinic? In: OlesenJ, editor. Headache classification and epidemiology.New York: Raven Press, 1994; 4: 77–86
3.
DahlöfC.The ideal 5HT1D agonist. In: OlesenJ, Tfelt-HansenP editors. Headache treatment: trial methodology and new drugs.Philadelphia: Lippincott-Raven, 1997: 243–51
MartinGR, MartinRS.Recurrent migraine following treatment with 5HT1D agonists: pharmacokinetic and pharmacodynamic aspects. In: SandlerM, FerrariMD, HarnettS editors. Migraine: pharmacology and genetics.London: Chapman & Hall, 1996: 94–108
6.
PloskerGL, McTavishD.Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs1994; 47: 622–51
7.
WinnerP, RicaldeO, Le ForceB, SaperJ, MargulB.A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol1996; 53: 180–4
8.
MartinGR, MartinRS.Recurrent migraine following treatment with 5HT1D agonists: pharmacokinetic and pharmacodynamic aspects. In: SandlerM, FerrariMD, HarnettS editors. Migraine: pharmacology and genetics.London: Chapman & Hall, 1996: 94–108
VisserWH, BuggraafJ, MullerLM. Pharmacokinetic differences between migraine patients with and without headache relief and between patients with and without headache recurrence after sumatriptan. Br J Clin Pharmacol1995; 39: 572
